KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical OfficerBusiness Wire • 05/03/21
KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824Benzinga • 04/20/21
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824Business Wire • 04/20/21
KalVista Pharmaceuticals, Inc. (KALV) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 03/17/21
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 03/11/21
KalVista Pharmaceuticals, Inc. (KALV) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 03/02/21
KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional SharesBusiness Wire • 02/16/21
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common StockBusiness Wire • 02/11/21
KALV Stock: 8 Things to Know About KalVista Pharmaceuticals as Shares Skyrocket TodayInvestorPlace • 02/09/21
Investors Cheer Positive Data From KalVista's KVD900 Mid-Stage Hereditary Angioedema TrialBenzinga • 02/09/21
Kalvista Rockets To 5-Year High On 'Overwhelmingly Positive' Test ResultsInvestors Business Daily • 02/09/21
KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE AttacksBusiness Wire • 02/09/21
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences TeamBusiness Wire • 01/26/21
Are Options Traders Betting on a Big Move in KalVista Pharmaceuticals (KALV) Stock?Zacks Investment Research • 01/11/21
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema FranchiseBusiness Wire • 10/15/20